Quantitative CT indexes are significantly associated with exercise oxygen desaturation in interstitial lung disease related to systemic sclerosis

Clinical Respiratory Journal

Volumn 11, Issue 6, 2017, Pages 983-989

  Ariani, Alarico ^a   Aiello, Marina ^b   Silva, Mario ^b   Alfieri, Veronica ^b   Bonati, Elisa ^b   Lumetti, Federica ^a   Delsante, Giovanni ^a   Sverzellati, Nicola ^b   Chetta, Alfredo ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

computer assisted radiographic image interpretation interstitial lung disease oxygen deficiency systemic sclerosis

Indexed keywords

ADULT; ARTICLE; CLINICAL OUTCOME; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; EXERCISE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; IMAGE SEGMENTATION; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OXYGEN DESATURATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIX MINUTE WALK TEST; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; AGED; ALGORITHM; COMPARATIVE STUDY; COMPLICATION; COMPUTER ASSISTED DIAGNOSIS; DEVICES; DIAGNOSTIC IMAGING; LUNG; METABOLISM; MORTALITY; OUTCOME ASSESSMENT; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; WALK TEST; X-RAY COMPUTED TOMOGRAPHY;

OXYGEN;

AGED; ALGORITHMS; FEMALE; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); OXYGEN; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; WALK TEST;

EID: 84959210973     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/crj.12451     Document Type: Article

References (40)

1. Chora I, Guiducci S, Manetti M, et al. Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis. Autoimmun Rev. 2015;14: 314–22.
2. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002;81: 139–53.
3. Strickland G, Pauling J, Cavill C, Shaddick G, McHugh N. Mortality in systemic sclerosis-a single centre study from the UK. Clin Rheumatol. 2013;32: 1533–9.
4. Pope J. Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler”s Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud”s Condition Score (RCS). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S98–111.
5. Swigris JJ, Zhou X, Wamboldt FS, et al. Exercise peripheral oxygen saturation (SpO2) accurately reflects arterial oxygen saturation (SaO2) and predicts mortality in systemic sclerosis. Thorax. 2009;64: 626–30.
6. Wilsher M, Good N, Hopkins R, et al. The six-minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease. Respirology. 2012;17: 647–52.
7. Wells AU, Behr J, Silver R. Outcome measures in the lung. Rheumatology. 2008;47(Suppl 5):v48−50.
8. Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution computed tomography in early scleroderma lung disease. J Rheumatol. 1991;18: 1520–8.
9. Wells AU. High-resolution computed tomography and scleroderma lung disease. Rheumatology (Oxford). 2008;47(Suppl 5):v59–61.
10. Goh NSL, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177: 1248–54.
11. Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology. 2013;52: 155–60.
12. Schmidt SL, Sundaram B, Flaherty KR. Diagnosing fibrotic lung disease: when is high-resolution computed tomography sufficient to make a diagnosis of idiopathic pulmonary fibrosis? Respirology. 2009;14: 934–39.
13. Aziz ZA, Wells AU, Hansell DM, et al. HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. Thorax. 2004;59: 506–11.
14. Park SC, Tan J, Wang X, et al. Computer-aided detection of early interstitial lung diseases using low-dose CT images. Phys Med Biol. 2011;56: 1139–53.
15. Kim HG, Tashkin DP, Clements PJ, et al. A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exp Rheumatol. 2010;28: S26–35.
16. Marten K, Dicken V, Kneitz C, et al. Interstitial lung disease associated with collagen vascular disorders: disease quantification using a computer-aided diagnosis tool. Eur Radiol. 2009;19: 324–32.
17. Goldin JG. Quantitative CT of the lung. Radiol Clin North Am. 2002;40: 145–62.
18. Sverzellati N, Zompatori M, De Luca G, et al. Evaluation of quantitative CT indexes in idiopathic interstitial pneumonitis using a low-dose technique. Eur J Radiol. 2005;56: 370–5.
19. Lynch DA. Quantitative CT of fibrotic interstitial lung disease. Chest. 2007;131: 643–4.
20. Ariani A, Lumetti F, Silva M, et al. Systemic sclerosis interstitial lung disease evaluation: comparison between semiquantitative and quantitative computed tomography assessments. J Biol Regul Homeost Agents. 2014;28: 507–13.
21. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72: 1747–55.
22. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85: 751–8.
23. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354: 2655–66.
24. La Montagna G, Cuomo G, Chiarolanza I, Ruocco L, Valentini G. [HAQ-DI Italian version in systemic sclerosis]. Reumatismo. 2006;58: 112–5.
25. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16: 5–40.
26. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC. Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16: 41–52.
27. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166: 111–7.
28. Ariani A, Carotti M, Gutierrez M, et al. Utility of an open-source DICOM viewer software (OsiriX) to assess pulmonary fibrosis in systemic sclerosis: preliminary results. Rheumatol Int. 2014;34: 511–6.
29. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2013:1–1. Available at: http://www.R-project.org/.
30. Camiciottoli G, Orlandi I, Bartolucci M, et al. Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life. Chest. 2007;131: 672–81.
31. Avouac J, Kowal-Bielecka O, Pittrow D, et al. Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Ann Rheum Dis. 2010;69: 1360–3.
32. Shin KE, Chung MJ, Jung MP, Choe BK, Lee KS. Quantitative computed tomographic indexes in diffuse interstitial lung disease: correlation with physiologic tests and computed tomography visual scores. J Comput Assist Tomogr. 2011;35: 266–71.
33. Diot E, Boissinot E, Asquier E, et al. Relationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosis. Chest. 1998;114: 1623–9.
34. MD AF, Bois MD du PR. Interstitial lung disease in connective tissue disorders. Lancet. 2012;380: 689–98.
35. Lota HK, Renzoni EA. Circulating biomarkers of interstitial lung disease in systemic sclerosis. Int J Rheumatol. 2012;2012: 121439.
36. Khanna D, Tseng C-H, Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum. 2011;63: 3078–85.
37. Khanna D, Kowal-Bielecka O, Khanna PP, et al. Quality indicator set for systemic sclerosis. Clin Exp Rheumatol. 2011;29: S33–9.
38. Khanna D, Clements PJ, Furst DE, et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the scleroderma lung study. Arthritis Rheum. 2005;52: 592–600.
39. Holland AE, Goh NSL. The six-minute walk test in scleroderma: what should we measure and how should we measure it? Respirology. 2012;17: 588–89.
40. Matucci-Cerinic M, Steen VD, Furst DE, Seibold JR. Clinical trials in systemic sclerosis: lessons learned and outcomes. Arthritis Res Ther. 2007;9 Suppl 2:S7.